Boston Scientific Corporation BSX NYSE

Boston Scientific Corporation (BSX) reported total assets of $43.67B and total liabilities of $19.2B for quarter ending 2025-12-31, resulting in total equity of $24.47B.

The company held $2.05B in cash and short-term investments. Total debt stood at $12.42B, with net debt of $10.37B. The Debt-to-Equity (D/E) ratio was 0.51 (moderate).

Current ratio is 1.62, indicating strong short-term liquidity. Interest coverage is 13.4x (strong).

Criteria supported by this page:

• HEALTH (83/100, Pass) — Debt-to-Equity of 0.51, current ratio of 1.62, interest coverage 13.4x — balance sheet is strong
• MOAT (80/100) — Total assets $43.67B and equity $24.47B support the company's competitive scale
• VALUE (51/100) — Debt-to-Equity 0.51 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 80/100 with 5/7 criteria passed.